Abstract:670 Background: Response rates with ICI are only about 20% in mUC and we lack validated biomarkers to select patients who are most likely to derive benefit from ICI. Programmed cell death ligand 1 (PD-L1) has not proven to be a useful biomarker. We need biomarkers of response and resistance to avoid nonbeneficial treatment (Tx) and spare the majority of pts who will not respond to ICI both physical and financial toxicity. Here we report tumor genomic correlates of response and resistance to ICI in pts with mUC. Methods: We identified 335 adult pts with mUC at the Cleveland Clinic treated who received > / = 2 cycles of ICI with pembrolizumab (P) or atezolizumab (A) between 2015 and 2023. Of the 335 pts, 49 had pre-Tx archival formalin fixed paraffin-embedded (FFPE) tissues available. Pts were categorized by their response to ICI as responders (R) (Complete Response (CR), Partial Response (PR), and Stable Disease (SD)) (N = 23) or non-responders (NR) (Progressive Disease (PD)) (N = 26). Whole exome sequencing was performed from macro dissected tumors. Raw data in FASTQ format was aligned to GRCh38 human reference genome, somatic mutations were called by Mutect2 (part of GATK4) and allele-specific copy-number analysis was performed by applying the Facets and Gistic2 package. Results: Comparison of our cohort Tumor Mutation Burden (TMB) with mutation burden of 33 the cancer genome atlas (TCGA) cohorts shows close similarity to TCGA bladder urothelial carcinoma (BCLA). Median TMB in our cohort was 6.46 muts/Mb. In our cohort, TP53 hotspot mutations were found in 52% of the (R) cohort compared to 31% in the (NR) cohort. Additionally, mutations in KMT2C and KMT2A were found in 26% and 22% of the (R) cohort compared to 8% and 12 % of the (NR) cohort. (R) also had increased mutations in the ARID1A (17% vs 4%) and ERBB2 (17% vs 4%) compared to (NR). FGFR3 missense mutations were seen in only 4% of (R) cohort compared to 15% in (NR). In our complete cohort, 49% of patients had ERBB2 copy number amplifications and 92% of patient had CREBP2 deletions. Conclusions: In our real-world cohort of mUC pts treated with ICI, we identified differential genomic alterations between (R) and (NR). High frequency of ERBB2 mutations and alterations in overall cohort and higher frequency in (R) suggests potential role for anti-HER2 therapies alone or in combination with ICI. Ongoing genomic and immunologic correlative studies in our cohort will further help understand biomarkers of response and resistance to ICI in pts with mUC.

Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab

Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.

A study of blood myeloid-derived suppressor cells for predicting pembrolizumab efficacy in patients with metastatic urothelial carcinoma.

Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan

Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review

The effect of postoperative pathological findings related to the eligibility of adjuvant immunotherapy on oncologic outcomes in patients with locally advanced urothelial cancer.

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project

PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study

Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis

Metastatic Urothelial Carcinoma With Sarcomatoid Subtype After Robot-Assisted Radical Cystectomy Successfully Treated With Pembrolizumab

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011

Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors

Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.